Anxiety, Depression, Ptsd
Conditions
Keywords
antidepressants, pharmacogenetics
Brief summary
The treatment of depression, anxiety disorders and post-traumatic stress disorder (PTSD) is a main public health problem due to the frequency of these pathologies and the very partial effectiveness of the existent therapies. These illnesses generally require the prescription of several successive lines of antidepressant treatments before the treatments actually become effective, leading to a several week delay during which the patient suffers from the symptoms of his/her pathology and is also likely to experience the side effects of the treatment. Pharmacogenetics is an individualized prescribing modality that aims to predict the most favorable treatment for a given individual based on the study of genetic variants of cytochromes. The main hypothesis of this research is that the use of pharmacogenetics in routine practice in a population of military personnel requiring a first prescription of an antidepressant is of interest to improve the tolerance and effectiveness of the treatment.
Interventions
BIOLOGICALBlood collection
A blood sample will be collected at enrollment to perform pharmacogenetics analyses.
OTHERQuestionnaires
Several questionnaires will be filled by the participants or by the clinicians at every study visits: Hospital anxiety depression scale (HAD), Post Traumatic Stress Disorder Checklist for DSM-5 (PCL-5), Quick inventory of depressive symptomatology - self rated (QiDS), Beck's Anxiety Inventory (BAI), World Health Organization Quality Of Life (WHOQOL-BREF), EuroQol Group questionnaire (EQ5D), Frequency, intensity, burden of side effects rating (FIBSER), Udvalg for Kliniske Undersøgelser - Side Effects Rating Scale - for Patients (UKU-SERS-PAT), Clinical Global impression (CGI), Montgomery and Asberg Depression Rating Scale (MADRS).
OTHERCognitive test battery (optional)
For patients participating in the ELAN ancillary study : the participants will undergo a battery of neurocognitive tests assessing motivation (élan vital in French).
Sponsors
Direction Centrale du Service de Santé des Armées
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Between 18 and 65 years-old; * To benefit from a medical follow-up in the psychiatric department of an army training hospital; * To present a pathology requiring an antidepressant treatment and whose prescription can wait 10 days; * To have given written informed consent to participate in the study.
Exclusion criteria
* To be currently treated with an antidepressant or antidepressant stopped less than 15 days ago; * To have one or more contraindication to the introduction of an antidepressant treatment; * Pregnancy or breastfeeding; * To require a measure of constraint.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients with a Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER) scale deleterious score ≤ 2 after 8 weeks of treatment | 8 weeks after antidepressant treatment initiation | This endpoint will allow to assess the clinical tolerance of antidepressant treatment and to compare the results between the 2 arms. The FIBSER scale score ranges from 0 to 18 with higher scores reflecting more deleterious side effects. |
Countries
France
Contacts
Primary ContactEmeric SAGUIN, MD
Outcome results
None listed